Verona Pharma (VRNA)
(Delayed Data from NSDQ)
$105.40 USD
-0.07 (-0.07%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $105.41 +0.01 (0.01%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
VRNA 105.40 -0.07(-0.07%)
Will VRNA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for VRNA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VRNA
Volatility-Proof Your Portfolio With VIPS, GDS, FUTU & VRNA Stocks
Merck Unveils Cost-Cutting Plan: Can it Create Long-Term Value?
VRNA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Merck Q2 Earnings Top, Sales Meet Estimates, 2025 View Narrowed
Merck Q2 Earnings in the Cards: Buy, Sell or Hold Ahead of Results?
SRPT Slides on Voluntary US Elevidys Shipment Pause Amid Scrutiny
Other News for VRNA
Janus Henderson Global Life Sciences Diversified ADR Managed Account Q2 2025 Commentary
Janus Henderson Venture Fund Q2 2025 Commentary
Putnam Large Cap Growth Fund Q2 2025 Commentary
Janus Henderson Global Life Sciences Fund Q2 2025 Commentary
Putnam Small Cap Growth Fund Q2 2025 Commentary